Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 20Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1

Interventions

Cyclophosphamide 17Rituximab 14Cytarabine 9Peripheral Blood Stem Cell Transplantation 7Melphalan 7Etoposide 7Filgrastim 6Dexamethasone 6fludarabine phosphate 5fludarabine 5Radiotherapy 5Cyclosporine 5Carmustine 5ibrutinib 4Vincristine 4Prednisone 4Lenalidomide 4Doxorubicin 4Bortezomib 4Sensitivity and Specificity 3R-CHOP protocol 3Mycophenolic Acid 3Interferon-alpha 3Indium 3Cisplatin 3Busulfan 3Bendamustine Hydrochloride 3Antilymphocyte Serum 3Antigens, CD19 3sargramostim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Mantle-Cell × ibritumomab tiuxetan × Clear all
NCT00397800 2012-08-28

Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma

Technical University of Munich

Phase 1/2 Unknown
12 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡